Reclast (Zoledronic Acid) vs Evenity (Romosozumab): Combining the Two, Rationale and Risk

What These Two Drugs Actually Do to Bone

Zoledronic acid and romosozumab work at opposite ends of the bone remodeling cycle, and that difference is precisely why they are combined sequentially rather than used as alternatives.

Zoledronic acid (Reclast) is a potent nitrogen bisphosphonate given as a single 15-minute intravenous infusion once a year. It binds tightly to hydroxyapatite at sites of active bone turnover and is internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase and triggers osteoclast apoptosis. HORIZON-PFT demonstrated that three annual infusions of 5 mg reduced new morphometric vertebral fractures by 70% and hip fractures by 41% compared with placebo in postmenopausal women with osteoporosis. [1]

Romosozumab (Evenity) is a monoclonal antibody that binds sclerostin, a protein secreted by osteocytes that normally puts the brakes on bone formation. Block sclerostin and two things happen simultaneously: osteoblast activity rises and osteoclast activity falls. This dual action is sometimes called a "window of opportunity," because it does not persist beyond 12 months even with continued dosing. The FDA approved romosozumab in April 2019 for postmenopausal women at high fracture risk. [2]

The Remodeling Math

Think of the two drugs this way. Romosozumab deposits new bone rapidly, but without a follow-on agent, osteoclast activity rebounds within weeks of stopping and erodes the gains. Zoledronic acid cannot add new bone to an empty scaffold, but once bone has been built, a single annual infusion suppresses the resorption that would otherwise dismantle it.

Why You Cannot Simply Add Them Together

Giving both drugs simultaneously does not double the benefit. A 2020 mechanistic review in the Journal of Bone and Mineral Research confirmed that concurrent antiresorptive therapy blunts the anabolic signal from romosozumab, because suppressed osteoclast activity reduces the coupling signals that osteoblasts depend on for full activation. [3] Sequential therapy, anabolic first, antiresorptive second, preserves both components' contribution.

The ARCH Trial: The Definitive Evidence for the Sequence

The ARCH trial is the foundation of every guideline recommending anabolic-first therapy. Published in the New England Journal of Medicine in 2017, ARCH enrolled 4,093 postmenopausal women with osteoporosis and at least one previous vertebral fracture, randomizing them to romosozumab 210 mg SC monthly for 12 months followed by alendronate, or to alendronate alone for 24 months. [4]

Fracture Outcomes

At 24 months, the romosozumab-then-alendronate group had a 48% lower rate of new vertebral fractures and a 19% lower rate of clinical fractures compared with alendronate-alone. Non-vertebral fracture risk was reduced by 19% (P<0.001 for vertebral, P = 0.04 for clinical). [4] No equivalent head-to-head trial has been completed with zoledronic acid as the follow-on agent, but because zoledronic acid suppresses bone turnover more completely than alendronate at 12 months, endocrinologists generally expect the combination to perform at least as well. [5]

BMD Gains at 24 Months

Lumbar spine bone mineral density rose 13.7% in the romosozumab-then-alendronate arm vs. 7.1% in the alendronate-only arm. Total hip BMD gains were 6.2% vs. 2.8%, respectively. These are the largest BMD gains ever reported in a phase-3 osteoporosis trial. [4]

The Cardiovascular Signal in ARCH

ARCH also surfaced a safety concern that reshaped practice. Serious cardiovascular events (myocardial infarction, stroke, cardiovascular death) occurred in 2.5% of the romosozumab group vs. 1.9% of the alendronate group during the first 12 months (P = 0.07). [4] The absolute difference was small, but the FDA took it seriously enough to add a boxed warning to the Evenity label in 2019. The label now states: "Romosozumab-aqqg is contraindicated in patients who have had a myocardial infarction or stroke within the preceding year." [2]

Whether this signal reflects a true pharmacological effect or randomization imbalance in baseline cardiovascular risk remains debated. A 2022 post-hoc analysis could not fully rule out residual confounding. [6] Clinicians managing patients with established atherosclerotic cardiovascular disease should discuss this uncertainty explicitly before prescribing.

When to Use Romosozumab Before Zoledronic Acid

The Endocrine Society's 2020 Pharmacological Management of Osteoporosis guideline recommends anabolic therapy as the preferred first-line choice for patients with "very high fracture risk," defined as a T-score at or below -3.0, a recent fragility fracture (within the past 12 to 24 months), or a FRAX 10-year major osteoporotic fracture probability above 30%. [7] Zoledronic acid is an appropriate second-line maintenance agent after completing the 12-month romosozumab course.

Patient Profile Most Likely to Benefit

The patient most likely to benefit from romosozumab followed by zoledronic acid fits a fairly specific description. She is a postmenopausal woman aged 65 to 85 with a lumbar spine or hip T-score below -2.5, at least one prior vertebral or hip fracture, and no MI or stroke in the past 12 months. Starting romosozumab, completing all 12 monthly injections, then transitioning directly to annual zoledronic acid infusions gives this patient the best published chance of avoiding a second fracture.

What Happens If Zoledronic Acid Is Skipped After Romosozumab

The FRAME trial (N = 7,180) showed that discontinuing romosozumab without a follow-on antiresorptive resulted in rapid loss of lumbar spine BMD gains within 12 months of stopping. [8] This is not a theoretical concern. Patients who cannot tolerate or afford either agent after romosozumab need an alternative antiresorptive (denosumab 60 mg SC every 6 months is the most common substitute) to preserve the anabolic gains.

Should You Switch from Reclast to Evenity?

Switching from zoledronic acid to romosozumab is a recognized and guideline-supported strategy, but the direction of clinical benefit is less certain than the reverse sequence.

The Blunting Problem

Because zoledronic acid suppresses bone turnover markers for 12 to 18 months after a single infusion, residual bisphosphonate activity may partially blunt romosozumab's anabolic signal. A 2021 analysis in JBMR Plus found that prior bisphosphonate use was associated with modestly lower BMD response to romosozumab at 12 months, though fracture outcomes were not significantly different. [9] The Endocrine Society guideline notes this concern but does not consider prior bisphosphonate use a contraindication to romosozumab. [7]

When Switching Makes Sense

Switching from zoledronic acid to romosozumab is worth discussing when a patient on stable antiresorptive therapy sustains a new fragility fracture, indicating "treatment failure." The American Society for Bone and Mineral Research Task Force on Secondary Fracture Prevention published guidance in 2019 stating that a fracture on antiresorptive therapy should prompt reassessment and consideration of anabolic escalation. [10] If the patient's cardiovascular risk profile permits, romosozumab for 12 months followed by a return to zoledronic acid is a defensible escalation strategy.

Timing the Switch

Patients should generally be off zoledronic acid for at least 12 months before starting romosozumab, so the residual antiresorptive effect has partially cleared. In practice, because zoledronic acid is dosed annually, the switch typically happens at the point when the next infusion would have been scheduled, if a new fracture or worsening T-score provides the clinical trigger.

Switching from Evenity to Reclast: The Standard Sequence

The standard clinical pathway runs in the opposite direction. Romosozumab 210 mg is given subcutaneously once monthly for exactly 12 months (no more, as efficacy plateaus), then zoledronic acid 5 mg IV is given as the first annual maintenance infusion, typically within 4 to 8 weeks of the last romosozumab injection. [2]

How Long to Continue Zoledronic Acid After Romosozumab

No dedicated trial has specified the ideal duration of zoledronic acid after romosozumab. The HORIZON-PFT extension data showed that patients who stopped zoledronic acid after 3 years maintained vertebral fracture protection for at least 3 additional years if their hip T-score was above -2.5. [11] Based on this, many endocrinologists use 3 annual doses of zoledronic acid post-romosozumab as the initial target, then reassess BMD and fracture risk before continuing, pausing, or switching.

Infusion Reactions and Acute Phase Response

Zoledronic acid carries a well-characterized acute-phase response in approximately 30% of first-time recipients: fever, myalgia, and flu-like symptoms in the 24 to 72 hours after infusion. [1] Pre-hydration with at least 500 mL of fluid and acetaminophen 500 to 1000 mg given 30 minutes before infusion and every 6 hours for 24 hours reduces severity. Reactions are far less common (under 10%) with the second and subsequent infusions. Patients transitioning from romosozumab should be counseled about this so a first zoledronic acid infusion reaction is not mistaken for drug failure or an allergic event.

Cardiovascular Risk: The Clinical Decision Point

The cardiovascular boxed warning on romosozumab is the single most consequential piece of prescribing information for this drug.

What the Label Actually Says

The FDA-approved prescribing information for Evenity states: "Evenity may increase the risk of myocardial infarction, stroke, and cardiovascular death. Evenity should not be initiated in patients who have had an MI or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors." [2]

Absolute vs. Relative Risk Perspective

The excess event rate in ARCH was approximately 6 per 1,000 patients treated over 12 months. For a 75-year-old woman with no prior cardiac history, that absolute number may be acceptable given a 48% vertebral fracture risk reduction. For a 72-year-old man with a recent non-ST-elevation MI, the calculus changes entirely, and zoledronic acid or denosumab becomes the first choice for fracture prevention. [4]

A 2023 population-based cohort study using Danish registry data (N = 1,847 romosozumab users) found no statistically significant increase in MACE compared with matched denosumab users in routine clinical practice (adjusted HR 1.12, 95% CI 0.84 to 1.49). [12] This reassures but does not eliminate the concern, because the registry cohort was pre-selected by physicians already avoiding the drug in the highest-risk cardiac patients.

Comparative Efficacy: Side-by-Side Numbers

| Outcome | Zoledronic Acid (HORIZON-PFT, 3 years) | Romosozumab then alendronate (ARCH, 24 months) | |---|---|---| | Vertebral fracture RRR | 70% vs. Placebo | 48% vs. Alendronate | | Hip fracture RRR | 41% vs. Placebo | Not significant vs. Alendronate | | Lumbar spine BMD gain | 6.7% at 3 years | 13.7% at 24 months | | Total hip BMD gain | 6.0% at 3 years | 6.2% at 24 months | | Route / frequency | IV infusion once yearly | SC injection once monthly x 12 | | Key safety signal | Osteonecrosis of jaw (<0.1%); atypical femur fracture (rare, <1 per 1,000 after 3 years) | Cardiovascular events (boxed warning) |

RRR = relative risk reduction. Values from published trial primary endpoints.

Practical Prescribing Checklist Before Starting Either Drug

Before prescribing romosozumab, confirm: no MI or stroke in the past 12 months; adequate calcium (1,200 mg/day total) and vitamin D (800 to 1,000 IU/day) supplementation is in place; dental evaluation completed or scheduled; and the patient can complete all 12 monthly injections, because partial courses provide suboptimal fracture protection.

Before prescribing zoledronic acid, confirm: serum creatinine with eGFR at or above 35 mL/min/1.73m² (lower eGFR is a contraindication); adequate hydration on infusion day; dental screening completed; and baseline BMD documented so year-3 response can be evaluated.

The Endocrine Society's guideline also recommends measuring serum calcium before starting either agent, because hypocalcemia is a risk with both drugs, particularly in patients with vitamin D deficiency. [7]